focal spasticity after stroke
Neurology · 2018–2018
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| botulinum toxin type A Treatment of adult patients with moderate to severe lower limb focal spasticity following a stroke. | Nov 2018 | Deferred | 3 individuals Stroke Recovery Association |
Who spoke
Stroke Recovery Association
What the PBS pays
$73M in government benefit over 2024–25, across 140,782 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.